Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting HER2 in other tumor types.

S Scholl1, P Beuzeboc, P Pouillart

  • 1Institut Curie, Paris, France. sscholl@curie.net

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|August 28, 2001
PubMed
Summary

Human epidermal growth factor receptor-2 (HER2) is overexpressed in many cancers. Anti-HER2 monoclonal antibodies, like trastuzumab, show promise for treating HER2-positive tumors beyond breast cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Corrigendum to "French ccAFU guidelines-update 2020-2022: Prostate cancer" [Prog. Urol 30 (12 S) (2020), pp S136-S251].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2021
Same author

[French ccAFU guidelines - update 2020-2022: prostate cancer].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2020
Same author

[French CCAFU guidelines on prostate cancer: hormone-sensitive metastatic prostate cancer-update 2020].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2020
Same author

[French ccAFU guidelines - Update 2018-2020: Prostate cancer].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2019
Same author

RETRACTED: Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020 : cancer de la prostate French ccAFU guidelines – Update 2018–2020: Prostate cancer

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2018

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunotherapy

Background:

  • Human epidermal growth factor receptor-2 (HER2) overexpression is prevalent in various cancers, including breast, ovarian, bladder, and non-small-cell lung cancer (NSCLC).
  • HER2 plays a role in tumor initiation and progression, often correlating with poor prognosis and predicting response to therapies.
  • Anti-HER2 monoclonal antibodies (MAbs) target the HER2 receptor in HER2-positive tumors.

Purpose of the Study:

  • To explore the therapeutic potential of anti-HER2 MAbs in HER2-positive tumors beyond breast cancer.
  • To evaluate the efficacy of trastuzumab in various HER2-amplified carcinomas.

Main Methods:

  • Review of clinical trials and in vitro studies on anti-HER2 MAbs.
  • Analysis of HER2 overexpression prevalence in different tumor types.
  • Assessment of trastuzumab's efficacy in preclinical models and clinical trials.

Main Results:

  • Trastuzumab (Herceptin) has demonstrated efficacy in HER2-positive metastatic breast cancer.
  • Preliminary in vitro studies show anti-HER2 MAbs inhibit proliferation of ovarian, gastric, and NSCLC cell lines overexpressing HER2.
  • Clinical trials are ongoing or planned for trastuzumab in NSCLC, bladder, and ovarian cancers.

Conclusions:

  • Anti-HER2 MAbs hold significant therapeutic potential for HER2-positive carcinomas beyond breast cancer.
  • Further clinical investigation is warranted to establish the role of trastuzumab in treating various HER2-amplified cancers.
  • Targeting HER2 offers a promising strategy for managing a broader spectrum of human carcinomas.

Related Experiment Videos